Immune Design (IMDZ) is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease.

Company has strong cash position (est. $139 million as of December 2017), positive working capital, solid product pipeline (e.g. G100, CMB305) and collaborative revenues with companies like Sanofi and Roche.

Large amount of insider buying with a total of 2.8 million shares between October 2017 and January 2018.

Due to the U.S. tax reform, IMDZ would be the ideal biotech takeover candidate in 2018.

Analyst consensus presently for IMDZ has a rating of “Buy” and the average price target for the company is $13.06. This represents an upside of 248% based on the last price from Wednesday, January 17, 2018.